Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 183-191

  Perdriger, A ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Disease modifying anti rheumatic drugs; Infliximab; Rheumatoid arthritis

Indexed keywords

EID: 77649342126     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3189     Document Type: Review

References (90)

1. Lundy SK, Sarkar S, Tesmer LA, Fox D. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther. 2007;9:202.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440.
4. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66 Suppl 3:iii2-iii22.
5. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother. 2007;8:2089-2107.
6. Maini SR. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:329-347.
7. Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol. 2006;24:38-44.
8. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
9. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15:353-366.
10. Catrina AI, Trollmo C, Af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 2005;52:61-72.
11. Wijbrandts CA, Remans PH, Klarenbeek PL, et al. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum. 2008;58:3330-3339.
12. Van Roon JA, Bijlsma JW, Lafeber FP. Diversity of regulatory T cells to control arthritis. Best Pract Res Clin Rheumatol. 2006;20:897-913.
13. Sarkar S, Fox DA. Regulatory T cell defects in rheumatoid arthritis. Arthritis Rheum. 2007;56:710-713.
14. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med. 2004;200:277-285.
15. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4LCD25hi T-regulatory cells. Blood. 2006;108:253-261.
16. Bayry J, Sibéril S, Triebel F, Tough DF, Kaveri SV. Rescuing CD4CCD25CCregulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today. 2007;12:548-552.
17. Van den Berg WB, van Lent PL, Joosten LA, Abdollahi-Roodsaz S, Koenders MI. Amplifying elements of arthritis and joint destruction. Ann Rheum Dis. 2007;66 Suppl 3:iii45-iii8.
18. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. 2007;9 Suppl 1:S1 (doi:10.1186/ar2165).
19. Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2008;67:620-624.
20. Chopin F, Garnero P, Le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:353-357.
21. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
22. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341-1359.
23. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932.
24. Lipsky PE, van der Heijde DM, St Clair EW, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
25. Maini RN, Breedveld FC, Kalden JR, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-1065.
26. St Clair EW, van der Heijde DM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-3434.
27. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.
28. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA; FARR study group. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol. 2006;24 Suppl 43:S77-S82.
29. van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129-2134.
30. Van der Kooij SM, Le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2008. doi:10.1136/ard.2008.093294.
31. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008;18:460-464.
32. Smolen JS, Han C, Bala M, et al; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020-1030.
33. Smolen JS, Van Der Heijde DM, St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54:702-710.
34. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis. 2008. doi 10.1136/ard.2008.090019.
35. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
36. Durez P, Malghem J, Toukap AN, et al. Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56:3919-3927.
37. Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 2006;54:47-53.
38. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol. 2004;31:1538-1545.
39. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 2005;18:21-27.
40. Vander Cruyssen B, Van Looy S, Wyns B, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006;8:R112.(doi 10.1186/AR2001).
41. Van Looy S, Vander Cruyssen B, Meeus J, et al. Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment. Engineering Application Artifical Intelligence. 2006;19:819-828.
42. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:1233-1238.
43. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford). 2007;46:529-532.
44. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 2007;46:1153-1156.
45. Ducoulombier V, Solau E, Coquerelle P, et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine. 2007;74:56-59.
46. Figueiredo IT, Morel J, Sany J, Combe B. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:18-23.
47. Flendrie M, Creemers MC, van Riel PL. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford). 2007;46:146-149.
48. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infiximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. J Clinthera. 2008;11:1939-1954.
49. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
50. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2008. doi:10.1136/ard.2008.092833.
51. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
52. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645-660.
53. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008. doi10.1111/J.1365-2133.2008.08728x.
54. Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions in patients with arthritis. Arthritis Res Ther. 2006;8:R131.
55. Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immuno-suppressive therapy in suppressing the formation of antibodies to infliximab in crohn disease. Gut. 2007;56:1226-1231.
56. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology. 2002;41:631-637.
57. Bingham S, Bush MH, Kerr MA, Emery P, Valadeo Barcelos AT. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with Infliximab and leflunomide. Arthritis Rheum. 2004;50:4072-4073.
58. Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of Leflunomide in combination with Infliximab in rheumatoid arthritis. Arthritis Rheum. 2004;51:228-232.
59. Perdriger A, Mariette X, Kuntz JL, et al; Club Rheumatismes et Inflammation. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol. 2006;33(5):865-869.
60. Hyrich KL, Symmons DP, Watson KD, Silman AJ; British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:1786-1794.
61. Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2009;68:33-39.
62. Kalden JR, Nüßlein HG, Wollenhaupt J, Burmester GR, Krüger K, Antoni C. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol. 2008;26:834-840.
63. Westhovens R, Yocum D, Han J, et al; START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075-1086.
64. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004;30:237-255.
65. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403-3412.
66. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. 2003;42:617-621.
67. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
68. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-2293.
69. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
70. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet. 2003;3:148-155.
71. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41 Suppl 3:S199-S203.
72. Hooper M, Chi E. Anti-TNF antibodies associated with different risk of latent tuberculosis activation. Am J Med. 2006;119:639-646.
73. Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis. 2008;198:1842-1850.
74. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE; The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819-836.
75. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-610.
76. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008;8:147-152.
77. Hamdi H, Mariette X, Godot V, et al; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8:R114.
78. Gomez-Reino JJ, Carmona L, Descalzo; for the biobadaser group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Care Res. 2007;57:756-761.
79. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twentysix cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
80. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-1751.
81. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
82. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
83. Beyer M, Steinhoff M, Anagnostopoulos I, Assaf C, Sterry W. Hepatosplenic T-cell lymphomas and theraphy with TNF-alpha-blocking biologics:a risk for psoriasis patients? J Dtsch Dermatol Ges. 2009 Jan 12. [epub ahead of print].
84. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 2001;44:1977-1983.
85. Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:81-92.
86. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol. 2008;28:445-455.
87. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242-251.
88. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G. The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. Congest Heart Fail. 2002;8:275-279.
89. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administrationdatabase. J Rheumatol. 2008. doi:10.3899/jrheumotol.080545.
90. Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNF alpha antagonists. Drugs. 2008;68:591-606.